Showing results (171-180 of 367) with videos related to
Sort By:
Pageof 37
Gastroenterology|July 10, 2003
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNAChristian Klein, C Thomas Bock, Heiner Wedemeyer, et al.Mabs|August 29, 2012
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodiesChristian Klein, Claudio Sustmann, Markus Thomas, et al.The Journal of Pharmacology and Experimental Therapeutics|August 14, 2012
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blockerFlavio Solca, Goeran Dahl, Andreas Zoephel, et al.The Journal of Biological Chemistry|January 31, 2006
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilizationYork Tomita, Natasha Marchenko, Susan Erster, et al.Journal of Molecular Biology|September 5, 2006
Archaeal N-terminal protein maturation commonly involves N-terminal acetylation: a large-scale proteomics surveyMichaela Falb, Michalis Aivaliotis, Carolina Garcia-Rizo, et al.Biomed Research International|May 12, 2018
Sensitive Detection of the Natural Killer Cell-Mediated Cytotoxicity of Anti-CD20 Antibodies and Its Impairment by B-Cell Receptor Pathway InhibitorsFloyd Hassenrück, Eva Knödgen, Elisa Göckeritz, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitorDavid C Fry, Charles Wartchow, Bradford Graves, et al.Archiv Der Pharmazie|November 29, 2025
Exploring Nirmatrelvir Derivatives Through P2 Substituent Modifications and Warhead Innovations Targeting the Main Protease of SARS-CoV-2Felipe Cardoso Prado Martins, Johannes Lang, Fernanda Dos Reis Rocho, et al.British Journal of Haematology|December 16, 2010
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsMichaela Patz, Polina Isaeva, Nche Forcob, et al.Molecular Cancer Therapeutics|January 12, 2011
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, et al.Pageof 37